Chugai Pharmaceutical

AdipoSeeds is a biotechnology company focused on addressing the global shortage of platelets by developing an innovative platelet-making system. The company utilizes mesenchymal stem cells to create platelets without the need for complex and costly gene transfer techniques. By pioneering a new blood supply system, AdipoSeeds aims to provide a cost-effective and safe solution for platelet-related treatments. Their technology offers fat-derived platelets that can be utilized in various applications, including blood products and wound care medicine, ultimately contributing to improved healthcare outcomes.

Preferred Networks, Inc. is a software development company based in Tokyo, Japan, founded in 2014. It specializes in real-time machine learning technologies and develops applications for the Internet of Things, focusing on deep learning, robotics, and data analytics. The company serves various sectors, including transportation systems, manufacturing, bio-healthcare, retail, automobile, healthcare, advertising, life sciences, public safety, network security, and public transportation. Preferred Networks integrates data from the physical and digital worlds to create advanced solutions for autonomous driving, machine tools, robotics, and medical diagnosis. Additionally, the company has a subsidiary in Burlingame, California, which supports its international operations.

iPS PORTAL, Inc., founded in 2014 and based in Kyoto, Japan, specializes in the development of instruments for analyzing and measuring cells. The company focuses on contract testing of induced pluripotent stem (iPS) cells, aiming to promote the widespread adoption of iPS cell technology. iPS PORTAL provides research and development outsourcing services that support the practical application of iPS cell technology. Its offerings include assistance in research, contract testing, development, concept planning, and training programs in cell culture for researchers. By facilitating these services, iPS PORTAL enables healthcare companies to enhance research efforts and expedite the commercialization of drug discovery and regenerative medicine.

TWO CELLS is engaged in the research and development of regeneration technology. The company was founded in April 2003 and is based in Tokyo, Japan.

Gen-Probe Incorporated specializes in the development, manufacturing, and marketing of nucleic acid probe-based products for the clinical diagnosis of human diseases and the screening of donated blood. The company's clinical diagnostic products, sold directly in the United States and through distributors internationally, include assays for detecting viral and non-viral microorganisms, as well as cancer markers. Key offerings include the AccuProbe and PACE product lines, which provide high-sensitivity detection of various pathogens. Additionally, Gen-Probe collaborates with partners such as Novartis, Siemens, and bioMérieux to distribute blood screening products globally and to develop new assays for industrial testing applications. The company is also engaged in the creation of NAT assays and instruments aimed at detecting harmful pathogens in environmental and manufacturing contexts.